Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.

Biotechnology

Education

Parthenon Therapeutics

Parthenon Therapeutics' headquarters in Cambridge, MA, United States

Laurent Audoly

Peter Cincotta

Christopher O’donnell

Irena Lerentracht Webster

Xinwei Sher

Heather Condurso

Susan G. MacDonald

Joseph Paul Eder

Melissa Lambeth Kemp

Marina Kochetkova

Rong Li

Ezogelin Oflazoglu-Gruyters

Paolo Provenzano

Michael Cecchini

Ellen Puré

Wolf Hervé Fridman

Mace Rothenberg

Antoine Italiano

Pamela Munster

Description

People (6)

Laurent Audoly

Susan G. MacDonald

Ziyin Wang

Joshua Merritt

Xinwei Sher

Sumita Roy

Jobs